Oxford BioMedica Share Price (OXB)

6.93 -0.22 (-3.08%) delayed: 6:03PM GMT
Bid price 6.80 Open price 6.93
Ask price 7.05 Prev close 7.15
High price 7.05 Spread 3.55%
Low price 6.66 Volume 7,215,305

Register now for FREE live Oxford BioMedica share prices, Oxford BioMedica stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Oxford BioMedica Level 2 Data, indepth research tools and investor commentary for Oxford BioMedica (OXB) and other London Stock Exchange equities.

Oxford BioMedica Share Price Chart

Advanced Charts >>

Register now for FREE Oxford BioMedica share price charts

Oxford BioMedica Share Price Information

Name Oxford BioMedica Epic OXB
Sector Pharmaceuticals & Biotechnology ISIN GB0006648157
Activites Oxford BioMedica plc is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Index n/a

Oxford BioMedica Key Numbers

Latest Share Price (p) 6.93 Net Gearing (%) 18.89
Market Capitalisation (£m) 177.82 Gross Gearing (%) 34.79
Shares in issue (m) 2,565.90 Debt Ratio 5.64
P/E Ratio -8.77 Debt-to-Equity Ratio 0.11
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.53
Dividend Yield (%) 0.00 Price to book value 19.98
Dividend cover (x) 0.00 ROCE -1.12
Earning per share (p) -0.79 EPS Growth (%) -3.95
52 week high / low 9.60 / 1.83 DPS Growth (%) n/a

Oxford BioMedica Director Deals

Dec.Date Type Director Pos No. of Shares
18/12/2014 BUY Tim Watts FD 300,000
16/12/2014 SELL Martin Diggle NED 85,797,333
01/12/2014 BUY Andrew Heath NED 150,000
26/11/2014 BUY Paul Blake ED 215,000
14/10/2014 BUY Paul Blake ED 243,902

More Oxford BioMedica Director Deals >>

Oxford BioMedica Company News

16:40 28/01/2015

Second Price Monitoring Extn

RNS Number : 4242D Oxford Biomedica PLC 28 January 2015   Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The closing auction call period is extended in this security for a further 5 minutes. Following...

16:35 28/01/2015

Price Monitoring Extension

RNS Number : 4236D Oxford Biomedica PLC 28 January 2015   Price Monitoring Extension Today's closing auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity...

15:07 27/01/2015

Oxford BioMedica downgraded by N+1

N+1 Singer has moderated its recommendation on UK based biopharmaceutical company Oxford BioMedica (LON:OXB) and moved to a 'hold' rating from 'buy' as the shares homed in on its unchanged 6.9 pence target. However, the broker was keen to point out that the share price has risen by 151 per cent...

More Oxford BioMedica Company News >>

Register now for FREE Oxford BioMedica company news

Oxford BioMedica Share Price Discussions

8 days ago

CANCER drug co. Oxford Biomedica charts (OXB)

OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles. So here is a new title This one has got the charts at the top again & has a link to the old one....

more than 1 year ago


Very strong rumours of a further predator around. CAT,WYEYH,JOHNSON&JOHNSON,MERCK to name a few.............could be an exciting week ...!

more than 1 year ago


Very strong rumours of a further predator.........CAT,JOHNSON&JOHNSON,WYETH,MERCK to name a few. Could be an interesting week..!

Register now for FREE Oxford BioMedica share price discussions